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Introduction

CD8
+ T-cell activation following viral infection is a tightly controlled process that does not only require stimulation of their antigen receptor, but also costimulation by membrane-bound ligands and cytokines from antigen-presenting cells (APCs) and CD4 + helper T cells [1, 2] . Costimulation provides activated CD8 + T cells with essential signals that prevent activation-induced cell death [1] . In addition, costimulation unlocks the full potential of CD8 + T cells, promoting proliferation, cytokine production, and cytotoxicity [1] . A large number costimulatory receptors have been identified, most notably CD28 and members of the TNF receptor superfamily [3, 4] . A molecule of particular interest for T-cell activation is the c-type lectin-like receptor natural killer group 2 member D (NKG2D), encoded by killer cell lectin like receptor K1 (Klrk1). NKG2D is an activating receptor that is expressed on cytotoxic cells such as NK cells, NKT cells, and γδ T cells [5] . NKG2D is not present on naïve murine CD8 + T cells, but is induced after antigen encounter [6] . Multiple ligands for NKG2D have been identified, including MICA, MICB, and ULBP1-6 in humans and Rae1α-ε, H60a-c, and MULT1 in mice [7] . NKG2D ligands are typically induced in response to stress factors such as infection or oncogenic transformation [5] . NKG2D ligands are also observed in absence of overt infection such as on bone marrow (BM) stroma [5] . NKG2D signals through the adaptor molecules DAP10 and DAP12, which mediate direct cytotoxic killing of target cells upon recognition of ligands by NK cells [8] . CD8 + T cells lack expression of DAP12 and in these cells NKG2D was proposed to function as a costimulatory receptor [9] . In vitro systems trying to establish the exact costimulatory role of NKG2D on CD8 + T cells have previously shown contradicting results [10, 11] . In vivo, NKG2D engagement using models systems with transgenic expression of its ligands enhances both effector and memory CD8 + T-cell responses [12] . However, hyperstimulation of costimulatory molecules may lead to superphysiological responses or conversely, cause anergy [13, 14] . The impact of NKG2D on T-cell priming is therefore best studied using NKG2D-deficient cells. However, NKG2D plays a role in development of NK and B cells [15] and Krk1 −/− mice have hyperresponsive NK cells. Studies in which NKG2D is specifically eliminated in CD8 + T cells are so far lacking. Currently, it is unknown whether, under physiological conditions, NKG2D functions as a costimulatory factor for CD8 + T-cell priming in vivo, or whether it only mediates direct effector responses to target cells expressing its ligands [15] . Here, we questioned whether NKG2D plays a role in CD8 + T-cell priming following viral infection, using models in which NKG2D is specifically eliminated in these cells. We show that NKG2D is not required for CD8 + T-cell expansion following viral infection and has a redundant role in mediating cytotoxicity. In contrast, cytokine production as well as their capacity to lower viral loads following infection was impaired in NKG2D-deficient CD8 + T cells. Reduced cytokine production by Klrk1 −/− CD8 + T cells could be overcome using an IL-15 superagonist. Thus, under physiological conditions, NKG2D plays a nonredundant role in priming antiviral effector CD8 + T cells for the production of cytokines.
Results
NKG2D deficiency impairs antiviral CD8 + T-cell responses
We questioned whether effector CD8 + T-cell responses are affected by the absence of NKG2D. First, we analyzed NKG2D expression on effector, memory precursor, and naïve T cells. in spleen and lymph nodes (LNs) (Fig. 1B) . In vitro restimulation with viral peptides also showed a strong reduction in IFN-γ production by Klrk1 −/− CD8 + T cells compared to controls (Fig. 1C) .
Thus, NKG2D deficiency impairs CD8 + T-cell responses against mCMV infection.
NKG2D deficiency does not affect naïve T-cell development
NKG2D deficiency impacts the development of NK and B cells [15] . Differences in effector T-cell responses of Klrk1 −/− mice may therefore be the result of alterations in the naïve T-cell pool. No differences were observed in the frequencies of thymic subpopulations, peripheral CD4 + and CD8 + T-cell populations, or in regulatory T cells of Klrk1 −/− mice compared to WT controls. Also, naïve, central memory, and effector memory CD8 + T-cell subpopulations were unaffected by deficiency for NKG2D ( Fig. 2A) .
The impact of NKG2D on T-cell development may only become apparent in a competitive setting. Therefore, WT and Klrk1 −/− BM cells were mixed in a 1:1 ratio and injected in lethally irradiated hosts to generate mixed BM chimeras (mBMCs). After reconstitution, no differences were observed in the ratio between WT and Klrk1 −/− cells, either in thymic subpopulations or in total CD8 + T cells (Fig. 2B ). In addition, the composition of CD8 + T-cell sub- Fig. 3C and D) . In summary, NKG2D-deficiency does not affect cell surface marker expression or homing of effector CD8 + T cells.
CD8
+ T-cell specific NKG2D deficiency impairs IFN-γ production NKG2D mediates NK-cell education and its deficiency increases their ability to fight mCMV infection [15] . Lymphocytic choriomeningitis virus (LCMV) is not controlled by NK cells, but by CD8 + T cells [18] . We therefore analyzed effector CD8 + T-cell expansion in WT and Klrk1 −/− mice 8 days after LCMV infection. We did not observe differences in the percentage of antigenspecific CD8 + T cells in spleen, LNs, and liver and found only a minor reduction in absolute D b Gp33 + cell numbers in spleen ( Fig.   4A ). This prompted us to investigate viral loads in Klrk1 −/− mice after mCMV infection. Indeed, we observed a persistent reduction in viral titers both at early and late time points after infection ( Fig. 4B ) that were lost when NK cells were depleted (Fig. 4C) . Thus, differences in NK-cell responses are responsible for changes in antigenic load in Klrk1 −/− mice after mCMV infection and may impact CD8 + T-cell expansion.
To negate the effect of differential NK-cell functionality, mBMCs were generated and infected with mCMV. Eight days after infection, no differences were observed between WT and Klrk1 
CD8 + T-cell expansion (Fig. 4D ). NKG2D has been shown to promote cell division in T cells after stimulation in vitro [19] . To test this in vivo, mBMCs were infected with mCMV and injected every second day with BrdU. On day 8 after infection, BrdU incorporation was analyzed in effector CD8 + T cells. We observed strong labeling of BrdU, indicative of rapid proliferation in all effector cells. However, no differences in BrdU incorporation were observed between WT and Klrk1 −/− donor cells (Fig. 4E ). Thus, NKG2D deficiency does not impair effector CD8 + T-cell proliferation in response to mCMV infection. Next, we assessed the functionality of Klrk1 −/− CD8 + T cells in mBMCs 8 days after mCMV infection. In vitro restimulation with CD3ε antibodies or viral peptides showed no differences in granzyme B expression (Fig. 4F ). However, NKG2D-deficient cells produced significantly less IFN-γ in response to restimulation (Fig. 4G ). To ensure a sufficient amount of WT help for 
expanding CD8
+ T cells, mBMCs were generated using WT and Klrk1 −/− BM mixed in a 3:1 ratio. Also under these conditions, total CD8 + T-cell expansion was unaffected by deficiency for NKG2D, whereas IFN-γ production was reduced upon mCMV infection (data not shown). Thus, IFN-γ production, but not CD8 + T-cell expansion is reduced in absence of NKG2D.
To investigate the impact of NKG2D-deficiency on CD8 + T cells in a second viral model, effector cell responses in mBMCs were analyzed 8 days after LCMV infection. Again, we did not observe changes in the ratio between WT and Klrk1 −/− donor cells of virus-specific CD8 + T cells compared to the ratio before infection (Fig. 4H ). In contrast, we observed a large reduction in the ability of Klrk1 −/− CD8 + T cells to produce IFN-γ, both after stimulation with CD3ε antibodies and viral peptides (Fig. 4I) . Thus, NKG2D promotes IFN-γ production by antiviral CD8 + effector T cells also after infection with LCMV. In summary, NKG2D deficiency does not affect antiviral CD8 + T-cell expansion, but reduces IFN-γ expression in these cells.
T-cell specific NKG2D deficiency impairs cytokine production, but not proliferation of CD8 + T cells
Next, we investigated whether the impaired ability of NKG2D-deficient CD8 + T cells to produce cytokines was also observed in T-cell specific NKG2D-deficient mice. Therefore, animals carrying an allele of NKG2D flanked by LoxP sites [20] were crossed with mice expressing cre recombinase behind the CD4 + promotor.
NKG2D
Fl/Fl CD4 Cre (NKG2D CKO ) mice and NKG2D Fl/Fl littermates were infected with mCMV and the CD8 + T-cell response was analyzed 7 days later. Again, we did not observe any differences in the relative and absolute numbers of virus-specific CD8 + T cells, both for the K b m57 and K b m139 epitopes (Fig. 5A ). In contrast, in vitro restimulation with peptides or with CD3ε antibodies showed that mice deficient for NKG2D produced significantly less IFN-γ and TNF ( Fig. 5B and C) . Interestingly, after stimulation with CD3 antibodies, but not with peptides, NKG2D mice also showed a reduced capacity to produce granzyme B (Fig. 5D ). This suggests that NKG2D deficiency may lead to reduced cytotoxic potential of effector CD8 + T cells only after a strong antigenic stimulus. 
NKG2D deficiency impairs control of viral replication by CD8
+ T cells
To allow direct analysis of the antiviral capacity of NKG2D-deficient CD8 + T cells, OT1 T cells were mixed with Klrk1 / OT1 cells in a 1:1 ratio and transferred to WT recipients. Next, recipients were infected with mCMV-SIINFEKL and donor cell expansion was analyzed after 8 days. Donor cells had strongly expanded and formed a significant fraction of the total CD8 + T-cell pool (Fig. 6A) . However, similar to our observations using mBMCs, NKG2D deficiency did not impact the ability of CD8 + T cells to expand in response to viral infection (Fig. 6B) . IFN-γ production, in contrast, was significantly impaired in Klrk1 / OT1 cells (Fig. 6C) . Thus, also in this transfer model, cytokine production but not proliferation is impaired in CD8 + cells lacking NKG2D.
To investigate the cytotoxic capacity of NKG2D-deficient CD8 resulted in a reduction of m57-pulsed cells, though it was much less potent than the SIINFEKL-directed response that is for more than 90% dependent on donor cells (Fig. 6C ). However, OT1 or Klrk1 / OT1 cells displayed no difference in their capacity to kill SIINFEKL-pulsed cells (Fig. 6D) . Thus, NKG2D deficiency does not reduce cytotoxicity of CD8 + T cells.
To investigate the ability of NKG2D-deficient CD8 + T cells to control viral replication, mice were transferred with OT1 or Klrk1 / OT1 cells. Next, animals were infected with mCMV-SIINFEKL or mCMV and virus titers were followed over time / OT1 cells (both CD45.2) were transferred in naïve WT (CD45.2) recipients. Twenty four hours after transfer, mice were infected with mCMV-SIINFEKL. Eight days after infection, splenocytes of naïve WT mice (CD45.1) were labeled with high, intermediate, or no levels of CFSE and pulsed with SIINFEKL, m57, or Flu peptides, respectively, and mixed in a 1:1:1 ratio. Cells were injected in infected animals and after 4 h, the ratio within donor cells was determined in the spleens of infected mice. Gates were set on CD45.1
/ OT1 cells were transferred in naïve WT recipients. Next, NK cells were depleted with αNK1.1 antibodies. Twenty four hours later, mice were infected with mCMV or mCMV-SIINFEKL. Viral titers were determined in spleens. Data show means ± SEM and are representative of two (D, E) or three (A-C) experiments with three to five mice per experiment. **p < 0.005, ***p < 0.001 (Student's t-test, ANOVA with Bonferroni's post-test or MannWhitney test).
in the spleen. On day 4 after infection, mice infected with mCMV-SIINFEKL showed significantly lower virus titers in the spleen compared to animals receiving mCMV (Fig. 6E) . Strikingly, Klrk1 / OT1 cells failed to provide protection against mCMV-SIINFEKL infection. Thus, NKG2D deficiency impairs the capacity of CD8 + T cells to control viral replication when strong antigens such as SIINFEKL are expressed by a pathogen. In summary, NKG2D deficiency does not affect the direct killing capacity of CD8 + T cells, but reduces its ability to control viral replication, most likely as a result of their impaired ability to produce cytokines.
NKG2D stimulation during priming promotes cytokine production
To investigate directly whether NKG2D stimulation during priming regulates the ability of CD8 + T cells to produce cytokines we used an in vitro model for effector cell differentiation [21] . Previously, we generated 3T3 cells overexpressing Rae1δ, Rae1ε, Mult1, and H60 ( Fig. 7A and [22, 23] ), the NKG2D ligands present in C57BL/6 mice. Purified OT-1 cells were stimulated with different concentrations of SIINFEKL peptide, after which they were placed on a monolayer of our 3T3 cell lines in the presence of IL-2. After 2 days, cytokine production was assessed upon peptide restimulation. Rae1δ, Rae1ε, and H60, but not Mult-1 promoted IFN-γ and TNF production in OT-1 T cells after suboptimal TCR stimulation (Fig. 7B-D) . This effect was mediated through transcriptional regulation, since IFN-γ mRNA levels closely correlated with protein expression (Fig. 7C and E) . Finally, we questioned whether CD8 + T cells are primed through Dap10 or Dap12. T cells of WT, Dap10 −/− , or Dap12 −/− mice were stimulated in vitro with anti-CD3ε antibodies, after which they were cultured for 2 days on 3T3 or 3T3-Rae1δ cells in the presence of IL-2. Peptide restimulation showed that Rae1δ promoted IFN-γ production in WT and Dap12 −/− cells, but failed to achieve this effect in Dap10 −/− cells (Fig. 7F) . Thus, Dap10-dependent NKG2D stimulation during priming regulates the ability of effector CD8 + T cells to produce cytokines through transcriptional control. 
IL-15 superagonist rescues the reduced ability of
Klrk1
−/− CD8 + T cells to produce IFN-γ
We next investigated whether CD8 + T cells stimulate NKG2D in cis, or whether other immune cell subsets are involved. In vitro generated effector CD8 + T cells did not express NKG2D ligands (Fig. 8A) . Therefore, we measured NKG2D ligands on classical dendritic cells (cDCs), plasmacytoid dendritic cells (pDCs), macrophages and B cells, which represent the main APC subsets, in mice infected 40 h prior with mCMV or in uninfected controls. Noninfected mice did not express NKG2D ligands on any of the investigated populations ( Fig. 8B and C and data not shown). However, infection resulted in upregulation of H60 on a subset of cDCs. H60-positive cDCs expressed lower levels of CD11c (Fig. 8D) , which is associated with an activated phenotype [24] . Thus, in vivo, NKG2D on CD8 + T cells is likely triggered in trans by H60 on cDCs during priming. NKG2D potentiates IL-15 signaling toward PI3 kinase to promote memory CD8
+ T-cell formation [16] . We questioned whether enhanced IL-15 signaling during priming in vivo could overcome the reduced capacity of NKG2D-deficient effector CD8 + T cells to produce IFN-γ. WT and Klrk1 −/− mice were infected with mCMV. After 2 days, mice were injected with PBS or with a mixture of IL-15 and IL-15Rα-F c fusion protein, which forms an IL-15 superagonist (IL-15SA) [25] . Eight days after infection, the ability of CD8 + T cells to produce IFN-γ was analyzed. IL-15SA
did not increase the capacity of WT CD8 + T cells to produce IFN-γ in response to peptide restimulation, indicating already optimal IL-15 access. However, production of IFN-γ by Klrk1 −/− cells was restored to WT levels after administration of IL-15SA (Fig. 8E) . Thus, IL-15 stimulation is able to overcome the reduced ability of Klrk1 −/− effector CD8 + T cells to produce IFN-γ.
Discussion
NKG2D was shown to be able to promote CD8 + T-cell proliferation, cytotoxicity, and cytokine proliferation in various experimental settings [19, 26] . However, due to the broad impact of NKG2D deficiency on key antiviral immune cell subsets [15] , until now it was unclear whether NKG2D is a costimulatory molecule for CD8 + T cells in vivo, or only targets them to cells expressing NKG2D ligands. We show that during viral infection, NKG2D is not required for CD8 + T-cell expansion. Also, NKG2D deficiency had a minor impact on cytotoxic potential, which only became apparent following strong stimuli. However, we demonstrate that NKG2D has a nonredundant costimulatory role on effector CD8 + T cells that potentiates their ability to produce cytokines. The impact of a particular costimulatory signal depends both on the regulation of ligands on APCs and on receptor expression on T cells. For example, CD27 and CD28 are both constitutively expressed on CD8 + T cells [27] . However, whereas CD28 ligands are broadly expressed, the CD27 ligand CD70 is only transiently induced on a restricted number of cells [27, 28] . Other costimulatory receptors, such as OX40 are only induced several days after infection [29] . CD28 is therefore important for the activation and expansion of naïve CD8 + T cells, whereas OX40
promotes survival of activated effector CD8 + T cells several days after initial antigen encounter [29] . Differential regulation of costimulatory ligands and their receptors appears to be a way in which the efficiency and magnitude of the effector response is fine-tuned to the requirements of a specific infection [30, 31] .
Our findings indicate that, in the case of viral infection, the costimulatory role of NKG2D is mostly restricted to regulation of cytokine production. Interestingly, infected mBMCs did not show a difference in granzyme B production between WT-and NKG2D-deficient cells after infection, whereas NKG2D CKO mice did. This may reflect an unappreciated role for NKG2D in CD4 + helper T-cell function.
The discrepancy of our data with in vitro studies that show a role for NKG2D in CD8
+ T-cell expansion [11, 19, 26] is possibly the result of differences in intensity of NKG2D stimulation. In CD8 + T cells, NKG2D is linked to DAP10 and signals to PI3 kinase (PI3K) [8] . PI3K is a potent signaling nexus that is able to promote proliferation, cytotoxicity, and cytokine production via various downstream signaling cascades [32] . The signal intensity upstream of PI3K controls which downstream pathways are activated. Low-intensity PI3K activation drives phosphorylation of Akt at Thr308, which is sufficient to induce cytokine production [33] . High-intensity PI3K stimulation results in activation of the mTOR signaling cascade, phosphorylating a second site on Akt (Ser473) that enhances proliferation and induces expression of cytotoxic molecules [2, 34] . Our findings suggest that CD8 + T cells encounter sufficient NKG2D ligands during priming to promote cytokine production, yet not enough to also drive proliferation in vivo. Since IL-15 is a potent inducer of PI3K-mediated effector cell functions [2] , this might explain why IL-15 superagonists were able to overcome the effects of NKG2D deficiency. In addition, cytokine production depends more on PI3K signaling than cytotoxicity. In NK cells, loss of the PI3K subunit p110δ prevented cytokine production, whereas cytotoxicity was preserved [35] . Our findings do not downplay the important role of NKG2D in control of viral infection. CMV expresses several immunoevasins, such as m152, which actively prevent surface expression of NKG2D ligands [36] . Infection with m152-deficient viruses therefore results in reduced viral titers, partially because of an enhanced T-cell response [37] . Indeed, NKG2D-deficient CD8 + T cells did have a reduced capacity to produce cytokines and had impaired capacity to control viral replication, both after mCMV and LCMV infection. Importantly, NKG2D-deficient effector CD8 + T cells were hyporesponsive to TCR engagement compared to WT cells, even in the absence of overt NKG2D ligation. Thus, NKG2D mediates both priming and direct target engagement of CD8 + T cells.
Our findings should be viewed within the limitations of our study, such as the restricted number of antigen-specific responses investigated. As shown in Fig. 7B , the effect of NKG2D-priming is optimal within a window of T-cell stimulation strength. Figure 5D shows that NKG2D may have a similar impact on regulation of cytotoxicity. We believe that our experiments show the role of NKG2D on CD8 + T-cell priming in the most physiological models to date. However, we should not disregard the discrepancy between the costimulatory potential of NKG2D shown by others [9, 10] and the actual role that we observe in vivo, which may depend on the antigens studied. It will be interesting to see whether NKG2D has a more potent role in CD8 + T-cell priming against other epitopes, most notably those of a tumor origin. In summary, we show that during viral infection, the role of NKG2D extends beyond the direct killing of ligandexpressing target cells and actively contributes to priming of effector CD8
+ T cells. Our findings have important implications for vaccine strategies against viruses and tumors that aim to exploit NKG2D signaling in CD8 + T cells to enhance their effectiveness.
Materials and methods
Mice
Mice were age-and sex-matched within experiments and handled according institutional and national guidelines. All animal experiments were performed after approval of our Institute's Animal Ethics Committee. C57BL/6 (B6), OT-1, B6 CD45.1, and CD4 Cre mice were purchased from The Jackson Laboratory. Dap10 −/− and Dap12 −/− mice were provided by M.
Fl/Fl , and Klrk1 / mice were generated as described previously [15, 20] . All lines were kept as breeding colonies in our local animal facility under specific pathogen-free conditions.
Surface and intracellular staining, Abs, and tetramers
Cell surface mAbs were purchased from eBioscience and BD Biosciences, except for Rae1ε (R&D systems). Antibodies against Rae1δ, Mult1, and H60 were made in-house [22, 23] . MHC class I tetramers were a kind gift of Dr. Anja ten Brinke (Sanquin Research). CFSE (Molecular Probes) and BrdU (BD Biosciences) labeling and staining were performed according to manufacturers' protocols. For BrdU labeling, mice were injected i.p. every second day with BrdU (0.8 mg). Intracellular staining was performed using the BD Fix/Perm kit (cytokines) or the BrdU flow kit (BrdU). Flow cytometry was measured on a FACScan, FACSCalibur, FACSVerse, or FACSAria (BD Biosciences) and analyzed with FlowJo software (Tree Star).
Viral infections and in vivo experiments
The BAC-derived murine CMV strain MW97.01 is biologically equivalent to the mCMV Smith strain (VR-1399; ATCC) and is referred to as mCMV [38] . mCMV strains were propagated on MEF. NK-cell depletion was accomplished by i.p. injection of anti-NK1.1 Abs (clone PK136; made in-house). Viral titers were determined on MEF by standard plaque assay. LCMV (Armstrong) was propagated on BMK cells according to standard protocol.
For in vivo IL-15 stimulation, mice were injected 48 h after infection with IL-15/IL-15-Ra-Fc (0.2 mg/0.93 mg; R&D Systems) as described [25] . BM recipients were lethally irradiated (9 Gy 
In vitro stimulations
For in vitro generation of effector cells, CD8 + T cells were purified from spleens by positive selection using the MACS cell separation system (Myltenyi), CFSE labeled, and cultured for 27 h with SIINFEKL peptide (Genscript) or agonistic anti-CD3ε (145-2C11) and anti-CD28 (37.51, eBioscience) antibodies in RPMI-1640 medium (PAN-Biotech), supplemented with 10% FCS (PANBiotech) and 2-ME (Sigma-Aldrich). Next, cells were washed and cultured for 2 days with 100 ng/mL IL-2. 3T3 and NKG2D-L 3T3 cells were generated previously [22, 23] . In costimulation assays, cells were cultured for 2 h in presence of Mytomycin C (10 μg/mL) to block proliferation. Next, cells were washed and plated out as a monolayer 24 h before transfer of activated CD8 + T cells. For cytokine staining, cells were first restimulated 4 h in vitro with 10 ng/mL peptides (Gp33-KAVYNFATC; m57-SCLEFWQRV; m139-TVYGFCLL; Ova-SIINFEKL) or 5 mg/mL anti-CD3ε (145-2C11) in the presence of Brefeldin A (eBioscience).
